(Q37854874)

24 August 2017

1 reference

title

When should prophylaxis therapy in inhibitor patients be considered? (English)

1 reference

24 August 2017

1

1 reference

24 August 2017

8

V Blanchette

1 reference

24 August 2017

G Auerswald

2

1 reference

24 August 2017

V Jimenez-Yuste

3

1 reference

24 August 2017

B A Konkle

4

1 reference

24 August 2017

T Lambert

5

1 reference

24 August 2017

M Morfini

6

1 reference

24 August 2017

E Santagostino

7

1 reference

24 August 2017

publication date

21 March 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

17

1 reference

24 August 2017

issue

5

1 reference

24 August 2017

page(s)

e849-57

1 reference

Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02494.X

Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02494.X

New approaches in the management of inhibitor patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02494.X

Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02494.X

Thrombin generation in haemophilia A patients with factor VIII inhibitors after infusion of recombinant factor VIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02494.X

Long‐term FEIBA prophylaxis does not prevent progression of existing joint disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02494.X

Prophylactic treatment with FEIBA of a haemophilia A patient with inhibitor: what are the costs, what are the benefits?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02494.X

A retrospective postlicensure survey of FEIBA efficacy and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02494.X

Successful self-infusion of activated prothrombin complex concentrate for prophylaxis in a child with a factor VIII inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02494.X

Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02494.X

Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02494.X

The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02494.X

Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02494.X

Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02494.X

Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02494.X

"Primary prophylaxis" with rFVIIa in a patient with severe haemophilia A and inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02494.X

Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02494.X

Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02494.X

Cellular localization and trafficking of tissue factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02494.X

Tissue factor trafficking in fibroblasts: involvement of protease-activated receptor-mediated cell signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02494.X

21 January 2018

FEIBA: mode of action

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02494.X

The application of bypassing-agent prophylaxis in haemophilia A patients with inhibitors: a meeting report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02494.X

Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02494.X

Immune tolerance for the treatment of factor VIII inhibitors--twenty years' 'bonn protocol'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02494.X

International workshop on immune tolerance induction: consensus recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02494.X

Comparison of the international immune tolerance registry and the North American immune tolerance registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02494.X

Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02494.X

European study on orthopaedic status of haemophilia patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02494.X

Consensus recommendations for use of central venous access devices in haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02494.X

Central venous access devices in haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02494.X

A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02494.X

A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2011.02494.X

10.1111/J.1365-2516.2011.02494.X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference